INOVIO is focused on developing and commercializing DNA medicines to help protect people from infectious diseases and help treat people with cancer and HPV-associated diseases. In the last several years INOVIO has had its data published in several prominent peer-reviewed medical journals including:
The Journal of Infectious Diseases
January 2022
Open Forum Infectious Diseases
December 2021
Nature Communications
May 2020
The Lancet Infectious Diseases
July 2019
Title | Disease Target | Product |
---|---|---|
A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle Vaccine — September 2011 |
Delivery | CELLECTRA |
Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses Vaccine — June 2019 |
Delivery | CELLECTRA |
© Copyright 2023 INOVIO Pharmaceuticals. All rights reserved.